Abstract
Purpose/Objective: Biochemical recurrence of prostate cancer after definitive or salvage local therapy in the absence of metastatic disease represents a group of men well suited for a novel therapeutic intervention. Imatinib mesylate (Gleevec®) is a protein-tyrosine kinase inhibitor which has previously been tested in men with androgen-independent and metastatic prostate cancer. This phase II study was undertaken to determine the safety and efficacy of imatinib mesylate in men with biochemical relapse of non-metastatic, androgen-sensitive prostate cancer following local therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
